The present disclosure provides (a) isolated immunogenic PAA polypeptides； (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides； (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide； (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions； and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
